Navigation Links
Derma Sciences, Inc. Hires the Investor Relations Group

PRINCETON, N.J., July 20 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, has retained the Investor Relations Group (IRG), a thirteen-year-old, award-winning corporate communications firm based in New York City, to serve as its national investor relations and public relations firm.

The IRG team will use proprietary competitive analysis strategies and extensive databases to target the broad scope of the investment community, including portfolio managers and analysts. IRG's program will include pre-qualified one-on-one introductions, e-mail to investment professionals that have opted-in for communication, and general traditional outreach. Simultaneously, IRG's public relations department will commence an outreach campaign targeting editors, writers, and segment producers of local and national trade and consumer online, print, radio, and broadcast media outlets. IRG's mandate is to produce gripping news content that describes the company's advanced wound care products while positioning the Derma Sciences executive management team as healthcare industry thought leaders.

IRG's corporate communications program includes new media and multimedia initiatives that involve the creation of broadcast-ready corporate videos, podcasts, and the creation of social networking, video service, and micro-blogging accounts. The Investor Relations Group was recently honored with a "Stevie Award" for Investor Relations Program of the Year and named a finalist in the Best Media Website category from the 2009 American Business Awards.

"This is an exciting time for Derma Sciences; we have a strong product pipeline and just recently announced the first commercial sales of our BIOGUARD barrier dressings," said Edward J. Quilty, Chairman and Chief Executive Officer of Derma Sciences Inc. "As we continue to reach our milestones, we look forward to working with IRG to communicate our company strategy, goals, and progress with the investment community, our shareholders, the healthcare industry, the media, and the public-at-large."

About the Investor Relations Group, Inc.

The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of public companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at

About Derma Sciences, Inc.

Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the University of Southern California in Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008. Results from this study are expected to be submitted to the FDA in Q2 of 2010.

For more information about Derma Sciences, Inc., visit

Forward-Looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the Securities and Exchange Commission.


    Derma Sciences, Inc.
    Edward J. Quilty
    Chairman and CEO
    (609) 514- 4744


    The Investor Relations Group
    Investor Relations:
    Rachel Colgate
    Michael Crawford
    Media Relations:
    Susan Morgenbesser

SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
6. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
9. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
10. Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications
11. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... November 24, 2015 --> ... research report released by Transparency Market Research, the global ... a CAGR of 17.5% during the period between 2014 ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends ... prenatal testing market to reach a valuation of US$2.38 ...
(Date:11/24/2015)... ... November 24, 2015 , ... In ... paramount. Insertion points for in-line sensors can represent a weak spot where leaking ... 781/784 series of retractable sensor housings , which are designed to tolerate extreme ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):